CYP1A1 and lung cancer: In lung cancer, CYP1A1 A-to-I RNA editing drives carcinogenesis through the CYP1A1-HO-1-PI3K/Akt axis [385], while edited miR-411–5p represents a potential target for reversing TKI resistance by targeting MET [386].